Stock AZT ARCTICZYMES TECHNOLOGIES ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 08:15:00 14/05/2024 pm IST 		5-day change 1st Jan Change
23 NOK +2.22% Intraday chart for ArcticZymes Technologies ASA -8.91% -45.24%
13/05 ArcticZymes Technologies ASA Announces Board Resignations CI
08/05 ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 170.1 229.6 3,074 4,735 3,623 1,170 1,170 -
Enterprise Value (EV) 1 138.5 229.6 3,074 4,552 3,393 1,968 984 978.2
P/E ratio -12.1 x -39.6 x 37 x 103 x 112 x 114 x 96.9 x 49.2 x
Yield - - - - - - - -
Capitalization / Revenue 2.55 x - 31.4 x 37 x 26.5 x 18 x 9.59 x 7.93 x
EV / Revenue 2.07 x - 31.4 x 35.6 x 24.8 x 16.5 x 8.06 x 6.63 x
EV / EBITDA -11.6 x - - 73.9 x 83.2 x 88.5 x 56.4 x 30.1 x
EV / FCF -6.6 x - - - - 86.5 x - -
FCF Yield -15.2% - - - - 1.16% - -
Price to Book 3.16 x - - 19.3 x 12.7 x 6.92 x 3.62 x 3.37 x
Nbr of stocks (in thousands) 48,335 48,335 48,335 50,371 50,571 50,871 50,871 -
Reference price 2 3.520 4.750 63.60 94.00 71.65 23.00 23.00 23.00
Announcement Date 30/01/19 21/04/20 28/01/21 26/04/22 02/02/23 01/02/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 66.8 - 97.82 128 137 118.9 122 147.5
EBITDA 1 -11.9 - - 61.57 40.8 22.24 17.45 32.46
EBIT 1 -14.17 - - 58.43 36.47 15.86 11.07 26.08
Operating Margin -21.21% - - 45.65% 26.63% 13.33% 9.07% 17.68%
Earnings before Tax (EBT) 1 -13.83 - - 59 42.14 24.88 15.07 30.08
Net income 1 -13.83 -6.386 83.12 46.38 33.11 18.72 12.06 23.76
Net margin -20.7% - 84.97% 36.23% 24.17% 15.74% 9.88% 16.11%
EPS 2 -0.2900 -0.1200 1.720 0.9100 0.6400 0.3700 0.2374 0.4678
Free Cash Flow 1 -20.99 - - - - 22.76 - -
FCF margin -31.42% - - - - 19.13% - -
FCF Conversion (EBITDA) - - - - - 102.32% - -
FCF Conversion (Net income) - - - - - 121.54% - -
Dividend per Share 2 - - - - - - - -
Announcement Date 30/01/19 21/04/20 28/01/21 26/04/22 02/02/23 01/02/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 21.42 25.6 40.5 49.2 30.36 29.3 28.15 31.19 28.22 31.15 28.38 29.94 29.24 30.34 32.47
EBITDA 1 5.982 8.986 20.8 27.9 9.539 2.434 0.98 6.117 6.844 7.262 2.017 5.689 3.947 5.007 6.247
EBIT 1 5.19 8.085 19.98 26.74 8.274 1.53 - 4.527 5.181 5.655 0.495 4.089 2.347 3.407 4.567
Operating Margin 24.23% 31.58% 49.33% 54.36% 27.26% 5.22% - 14.51% 18.36% 18.15% 1.74% 13.66% 8.03% 11.23% 14.07%
Earnings before Tax (EBT) 1 5.724 8.453 19.89 26.69 11.17 3.233 1.049 6.315 7.412 8.435 2.715 4.589 2.847 3.907 4.238
Net income 1 4.702 6.886 15.44 20.82 8.751 2.492 1.054 5.039 5.604 6.061 2.017 3.671 2.278 3.126 3.487
Net margin 21.95% 26.9% 38.12% 42.31% 28.83% 8.51% 3.74% 16.16% 19.86% 19.46% 7.11% 12.26% 7.79% 10.3% 10.74%
EPS 2 0.1000 0.1300 0.3000 0.4100 0.1700 0.0500 0.0200 0.1000 0.1100 0.1200 0.0400 0.0722 0.0448 0.0614 0.0685
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 19/08/21 28/10/21 26/04/22 28/04/22 18/08/22 27/10/22 02/02/23 04/05/23 17/08/23 02/11/23 01/02/24 - - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 31.7 - - 183 230 168 186 192
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -21 - - - - 22.8 - -
ROE (net income / shareholders' equity) -28% - - 21.1% 12.5% 6.31% 3.82% 7.11%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.120 - - 4.860 5.640 6.070 6.350 6.820
Cash Flow per Share - - - - - - - -
Capex 1 1.28 - - - - 19.2 - -
Capex / Sales 1.92% - - - - 16.16% - -
Announcement Date 30/01/19 21/04/20 28/01/21 26/04/22 02/02/23 01/02/24 - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ArcticZymes Technologies ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
23 NOK
Average target price
25 NOK
Spread / Average Target
+8.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCTICZYMES TECHNOLOGIES ASA Stock ArcticZymes Technologies ASA
-45.24% 11Cr
MODERNA, INC. Stock Moderna, Inc.
+29.03% 4.82TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 4.17TCr
LONZA GROUP AG Stock Lonza Group AG
+43.45% 4.1TCr
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 2.88TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.48% 2.56TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.74% 1.9TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.06% 1.29TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.01% 1.2TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.51% 1.18TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZT Stock
  4. Financials ArcticZymes Technologies ASA
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW